Home › Biotheranostics Settles False Claims Allegations With DOJ for $2M

Biotheranostics Settles False Claims Allegations With DOJ for $2M

Apr 20, 2018

NEW YORK (GenomeWeb) – The US Department of Justice said on Thursday that Biotheranostics has agreed to pay $2 million to settle allegations that the company improperly billed Medicare for molecular breast cancer tests. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Cancer

  1. Foundation Medicine, Novartis Partner to Develop CDx for Oncology Drugs

  2. Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

  3. FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug

  4. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  5. Cancer Genetics, GeneCast Ink Cancer Test Distribution Deal

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.